Hospital market of Russia: results of the first 9 months of 2014
Print
19 January 2015
market-access-solutions.com
According to Hospital Audit of procurement in Russia ™, hospital market value in the first nine months of 2014. increased by 16% in real terms and amounted to 485,489,000. packages. In monetary terms, the market showed positive dynamics in rubles (+ 22%) and the dollar (+ 9%), and was equal to 101.717 billion. Rubles (2,870 bln. Dollars.) In wholesale prices.
The average price of drug unit in the hospital sector of the country in the first nine months of 2014. was equal to US $ 5.91., a year earlier - 6.25 dollars.
In the first three quarters of 2014 leading position in the hospital market has taken the company GLAXOSMITHKLINE, which is due to 35% increase purchases rose to this position with a third. Tops the list of previously SANOFI-AVENTIS (-3%) showed a negative trend and dropped to the second position. Another five representatives of "tens", as well as its leader, showed a rating progress. This company ABBVIE (+ 30%), JOHNSON & JOHNSON (+ 34%), NYCOMED / TAKEDA (+ 22%), ASTRAZENECA (+ 7%) and the only representative of the new rating BAYER (+ 21%), who finished third and fifth position, as well as a place from 7 to 9 inclusive. At the same time manufacturers ROCHE (+ 2%) and MERCK SHARP DOHME (+ 7%) dropped two points down at 4 and 6 lines. The last position in the ranking of preserving Nile for a NOVARTIS (+ 6%). The total share accumulated by ten leading producers decreased from 36.4% to 34.2%.
Numerous rearrangements occurred in the ranking of trade names. However, two of its members, drug Prezista (+ 34%) and Isentress (+ 33%), managed to maintain its position, the third and ninth, unchanged. Four other trade names in the "top ten" showed outperformance and improved their rating positions. This raised line up on the first and sixth places, Kaletra (+ 31%) and Herceptin (+ 32%), as well as representatives of the new Top 10 Epzicom (+ 94%) and tuberculin (purchases grew 171 times) who finished fourth and eighth positions. Less dynamic name Sodium chloride (+ 17%), Clexane (+ 3%), Reyataz (+ 15%) and Curosurf (+ 17%), in contrast, fell to lower positions, second, fifth, seventh and tenth. The total share of the top ten trade names increased by 1.5 percentage points and reached 14.9%.
In the ranking of leading INNs and combinations three new representative. This TUBERCULIN TEST (purchases increased 8.1 times), up from 68 in the third place, as well as ABACAVIR + LAMIVUDINE (+ 94%) and TRASTUZUMAB (+ 32%), which took 8 and 10 lines. In addition, the leader of the ranking has changed - in the first place from the second moved combination LOPINAVIR + RITONAVIR (+ 31%). Simultaneously, five representatives of "tens" went down to a lower position. On a line downwards shifted INN SODIUM (+ 18%), ENOXAPARIN SODIUM (+ 11%) and IMMUNOGLOBULIN BASE (+ 4%), whereas CEFTRIAXONE (-1%) and MEROPENEM (+ 16%) lost two rating points. Name DARUNAVIR (+ 34%) is still ranked fourth. Cumulative share of leading "tens" INN increased by 1.6 percentage points and was 17.2%.
Rating ATC groups on the hospital market showed high stability - seven of his representatives were engaged in the last field. It takes the first seven lines of the group J05 Antivirals for systemic effects (+ 32%), J01 Antibacterials for systemic use (+ 14%), L01 Antineoplastic (+ 17%), B05 Plazmazameschayuschie and perfusion solutions (+ 5%), B01 anticoagulants (+ 17%), J07 Vaccines (+ 13%) and V08 Contrast media (+ 21%). Eighth and ninth places were taken by representatives of the new Top 10, L04 Immunosuppressants (+ 39%) and J04 Drugs active against mycobacteria, which purchases increased by 2.9 times. On the last line dropped less dynamic N05 psychotropic drugs (+ 9%). The total share of the leading "tens" decreased from 60.8% to 60.1%.
Conclusion. Russian hospital market in the first three quarters of 2014. increased by 22% in rubles and 9% - in dollars, and was equal to 101.717 billion. rubles (2,870 bln. dollars.). In physical terms, the market showed a significant positive trend (+ 16%) and reached 485 489 000. Packages. The average price of drug unit in the hospital sector of the country in the first nine months of 2014. was equal to 5.91 dollars., whereas a year earlier to $ 6.25.
Source: remedium.ru
In the first three quarters of 2014 leading position in the hospital market has taken the company GLAXOSMITHKLINE, which is due to 35% increase purchases rose to this position with a third. Tops the list of previously SANOFI-AVENTIS (-3%) showed a negative trend and dropped to the second position. Another five representatives of "tens", as well as its leader, showed a rating progress. This company ABBVIE (+ 30%), JOHNSON & JOHNSON (+ 34%), NYCOMED / TAKEDA (+ 22%), ASTRAZENECA (+ 7%) and the only representative of the new rating BAYER (+ 21%), who finished third and fifth position, as well as a place from 7 to 9 inclusive. At the same time manufacturers ROCHE (+ 2%) and MERCK SHARP DOHME (+ 7%) dropped two points down at 4 and 6 lines. The last position in the ranking of preserving Nile for a NOVARTIS (+ 6%). The total share accumulated by ten leading producers decreased from 36.4% to 34.2%.
Numerous rearrangements occurred in the ranking of trade names. However, two of its members, drug Prezista (+ 34%) and Isentress (+ 33%), managed to maintain its position, the third and ninth, unchanged. Four other trade names in the "top ten" showed outperformance and improved their rating positions. This raised line up on the first and sixth places, Kaletra (+ 31%) and Herceptin (+ 32%), as well as representatives of the new Top 10 Epzicom (+ 94%) and tuberculin (purchases grew 171 times) who finished fourth and eighth positions. Less dynamic name Sodium chloride (+ 17%), Clexane (+ 3%), Reyataz (+ 15%) and Curosurf (+ 17%), in contrast, fell to lower positions, second, fifth, seventh and tenth. The total share of the top ten trade names increased by 1.5 percentage points and reached 14.9%.
In the ranking of leading INNs and combinations three new representative. This TUBERCULIN TEST (purchases increased 8.1 times), up from 68 in the third place, as well as ABACAVIR + LAMIVUDINE (+ 94%) and TRASTUZUMAB (+ 32%), which took 8 and 10 lines. In addition, the leader of the ranking has changed - in the first place from the second moved combination LOPINAVIR + RITONAVIR (+ 31%). Simultaneously, five representatives of "tens" went down to a lower position. On a line downwards shifted INN SODIUM (+ 18%), ENOXAPARIN SODIUM (+ 11%) and IMMUNOGLOBULIN BASE (+ 4%), whereas CEFTRIAXONE (-1%) and MEROPENEM (+ 16%) lost two rating points. Name DARUNAVIR (+ 34%) is still ranked fourth. Cumulative share of leading "tens" INN increased by 1.6 percentage points and was 17.2%.
Rating ATC groups on the hospital market showed high stability - seven of his representatives were engaged in the last field. It takes the first seven lines of the group J05 Antivirals for systemic effects (+ 32%), J01 Antibacterials for systemic use (+ 14%), L01 Antineoplastic (+ 17%), B05 Plazmazameschayuschie and perfusion solutions (+ 5%), B01 anticoagulants (+ 17%), J07 Vaccines (+ 13%) and V08 Contrast media (+ 21%). Eighth and ninth places were taken by representatives of the new Top 10, L04 Immunosuppressants (+ 39%) and J04 Drugs active against mycobacteria, which purchases increased by 2.9 times. On the last line dropped less dynamic N05 psychotropic drugs (+ 9%). The total share of the leading "tens" decreased from 60.8% to 60.1%.
Conclusion. Russian hospital market in the first three quarters of 2014. increased by 22% in rubles and 9% - in dollars, and was equal to 101.717 billion. rubles (2,870 bln. dollars.). In physical terms, the market showed a significant positive trend (+ 16%) and reached 485 489 000. Packages. The average price of drug unit in the hospital sector of the country in the first nine months of 2014. was equal to 5.91 dollars., whereas a year earlier to $ 6.25.
Source: remedium.ru
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.